Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Jan. 10, 2025 — Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen ...